GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ortin Laboratories Ltd (BOM:539287) » Definitions » Cyclically Adjusted PS Ratio

Ortin Laboratories (BOM:539287) Cyclically Adjusted PS Ratio : 0.21 (As of Jun. 19, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Ortin Laboratories Cyclically Adjusted PS Ratio?

As of today (2024-06-19), Ortin Laboratories's current share price is ₹20.48. Ortin Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₹98.63. Ortin Laboratories's Cyclically Adjusted PS Ratio for today is 0.21.

The historical rank and industry rank for Ortin Laboratories's Cyclically Adjusted PS Ratio or its related term are showing as below:

BOM:539287' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.13   Med: 0.21   Max: 0.39
Current: 0.19

During the past years, Ortin Laboratories's highest Cyclically Adjusted PS Ratio was 0.39. The lowest was 0.13. And the median was 0.21.

BOM:539287's Cyclically Adjusted PS Ratio is ranked better than
93.67% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs BOM:539287: 0.19

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ortin Laboratories's adjusted revenue per share data for the three months ended in Mar. 2024 was ₹0.178. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹98.63 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ortin Laboratories Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Ortin Laboratories's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ortin Laboratories Cyclically Adjusted PS Ratio Chart

Ortin Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.27 0.20 0.16 0.18

Ortin Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.22 0.19 0.23 0.18

Competitive Comparison of Ortin Laboratories's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Ortin Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ortin Laboratories's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ortin Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ortin Laboratories's Cyclically Adjusted PS Ratio falls into.



Ortin Laboratories Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Ortin Laboratories's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=20.48/98.63
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ortin Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ortin Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.178/153.0345*153.0345
=0.178

Current CPI (Mar. 2024) = 153.0345.

Ortin Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 8.063 94.103 13.112
201409 13.435 96.780 21.244
201412 11.007 96.780 17.405
201503 2.216 97.163 3.490
201506 15.051 99.841 23.070
201509 8.465 101.753 12.731
201512 15.997 102.901 23.791
201603 21.153 102.518 31.576
201606 15.166 105.961 21.904
201609 10.772 105.961 15.557
201612 12.845 105.196 18.686
201703 24.754 105.196 36.011
201706 13.471 107.109 19.247
201709 13.638 109.021 19.144
201712 21.889 109.404 30.618
201803 51.017 109.786 71.114
201806 40.830 111.317 56.132
201809 53.946 115.142 71.699
201812 57.468 115.142 76.380
201903 53.861 118.202 69.733
201906 48.851 120.880 61.846
201909 37.074 123.175 46.061
201912 66.819 126.235 81.004
202003 85.389 124.705 104.787
202006 94.470 127.000 113.836
202009 93.852 130.118 110.381
202012 63.392 130.889 74.117
202103 -241.169 131.771 -280.087
202106 2.396 134.084 2.735
202109 2.984 135.847 3.362
202112 2.025 138.161 2.243
202203 2.508 138.822 2.765
202206 3.193 142.347 3.433
202209 0.973 144.661 1.029
202212 1.421 145.763 1.492
202303 1.904 146.865 1.984
202306 1.916 150.280 1.951
202309 0.320 151.492 0.323
202312 0.167 152.924 0.167
202403 0.178 153.035 0.178

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ortin Laboratories  (BOM:539287) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Ortin Laboratories Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Ortin Laboratories's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ortin Laboratories (BOM:539287) Business Description

Traded in Other Exchanges
Address
Street no. 3, D. No. 1-8-B4, Ground Floor,Block-4, F3 HIG, Baghlingampally, Hyderabad, TG, IND, 500 044
Ortin Laboratories Ltd is an India based engaged in the manufacturing and trading of Pharmaceuticals, Drugs, and Intermediates. Its formulations include anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, antibiotics, antifungal, cephalosporins, and others. Some of its APIs Intermediates include Ciprofloxacin, Tramadol, Efavarenz, Lamivudine, Zudavudine, Nevirapine, Lopinavir, Fluconazole, Triclabendazole, Omeprazole, and others.It earns key revenue from domestic sales.

Ortin Laboratories (BOM:539287) Headlines

No Headlines